secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0000950170-24-104575
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024
--------------------------------------------------------------------------------

- Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.
- As of March 7, 2024, 40 patients enrolled across 6 dose levels (24-212 mg); no DLTs or study-drug-related SAEs reported.
- Dose-dependent decreases in SMARCA2 levels observed; RECIST partial responses and tumor shrinkage noted in heavily pretreated NSCLC and esophageal cancer.
- Company will host investor webcast on September 13, 2024 at 12:00 PM EST following oral presentation at ESMO Congress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/0000950170-24-104575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/prld-20240909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-104575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer